Quarterly UpdatesApr 13, 2026, 08:02 AM
CVRx Q1 2026 Revenue Expected Up 20% to $14.7M-$14.8M
AI Summary
CVRx, Inc. announced preliminary unaudited first quarter 2026 results, expecting revenue between $14.7 million and $14.8 million, representing approximately 20% growth year-over-year. The company also anticipates a gross margin of around 87%. Additionally, CVRx reported an increase in the 30-day approval rate for Medicare Advantage prior authorizations to 50% and activated the first site for its BENEFIT-HF clinical trial, which could significantly expand Barostim's patient population.
Key Highlights
- Q1 2026 revenue expected to be $14.7M-$14.8M, up 20% YoY.
- Gross margin for Q1 2026 expected at approximately 87%.
- Cash and cash equivalents were ~$72.3M as of March 31, 2026.
- Medicare Advantage 30-day approval rate reached 50% in early 2026.
- First site activated for BENEFIT-HF clinical trial on March 31, 2026.